<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8603">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02994953</url>
  </required_header>
  <id_info>
    <org_study_id>MS201781_0031</org_study_id>
    <nct_id>NCT02994953</nct_id>
  </id_info>
  <brief_title>A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12)</brief_title>
  <acronym>COMBO</acronym>
  <official_title>A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, and maximum tolerated
      dose (MTD) of NHS-IL12 when given in combination with a fixed avelumab dose in subjects with
      metastatic or locally advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence and Severity of Treatment Emergent Adverse Events (TEAEs) and related TEAEs</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of TEAEs and related TEAEs</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve from time of dosing to the time of the last observation (AUC0-t) of Avelumab and NHS-IL12</measure>
    <time_frame>Pre-dose; 1, 4, 8 hours post-infusion (Day 1); Day 2, 3, 8, 11 post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time Curve from time of dosing to infinity (AUC0-inf) of Avelumab and NHS-IL12</measure>
    <time_frame>Pre-dose; 1, 4, 8 hours post-infusion (Day 1); Day 2, 3, 8, 11 post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant (λz) of Avelumab and NHS-IL12</measure>
    <time_frame>Pre-dose; 1, 4, 8 hours post-infusion (Day 1); Day 2, 3, 8, 11 post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of Avelumab and NHS-IL12</measure>
    <time_frame>Pre-dose; 1, 4, 8 hours post-infusion (Day 1); Day 2, 3, 8, 11 post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum serum concentration (Cmin) of Avelumab and NHS-IL12</measure>
    <time_frame>Pre-dose; 1, 4, 8 hours post-infusion (Day 1); Day 2, 3, 8, 11 post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration Cmax (Tmax) of Avelumab and NHS-IL12</measure>
    <time_frame>Pre-dose; 1, 4, 8 hours post-infusion (Day 1); Day 2, 3, 8, 11 post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life (t1/2) of Avelumab and NHS-IL12</measure>
    <time_frame>Pre-dose; 1, 4, 8 hours post-infusion (Day 1); Day 2, 3, 8, 11 post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody (ADA) Serum Concentration</measure>
    <time_frame>Pre-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Best Overall Response (BOR) according to RECIST v1.1 criteria</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune-related BOR Using Immune-related Response Criteria, derived from RECIST v1.1.</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Avelumab and NHS-IL12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Subjects will receive avelumab intravenous (IV) infusion every 2 weeks on Day 1 and Day 15 of each cycle.</description>
    <arm_group_label>Avelumab and NHS-IL12</arm_group_label>
    <other_name>MSB0010718C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NHS-IL12</intervention_name>
    <description>Subjects will receive Subcutaneous (SC) injection of NHS-IL12 in escalating doses on Day 1 of each cycle.</description>
    <arm_group_label>Avelumab and NHS-IL12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have signed written informed consent.

          -  Male or female subjects age greater than equals to (&gt;=)18 years.

          -  Subjects must have histologically or cytologically proven metastatic or locally
             advanced solid tumors for which no standard therapy exists, standard therapy has
             failed, or subject is intolerant of established therapy known to provide clinical
             benefit for their condition.

          -  Subjects who have been treated previously with a checkpoint inhibitor may enroll.

          -  At least 1 unidimensional radiographically measurable lesion based on Response
             Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1), except for subjects
             with metastatic castration-resistant prostate cancer (CRPC) or metastatic breast
             cancer who may be enrolled with objective evidence of disease without a measureable
             lesion.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at Screening

          -  Estimated life expectancy of more than 12 weeks

          -  Adequate hematological function as defined below:

               -  White blood cells (WBC) count &gt;= 3.0 × 10^9 per liter (/L)

               -  Absolute neutrophil count &gt;= 1.5 × 10^9/L

               -  Lymphocyte count &gt;= 0.5 × 10^9/L

               -  Platelet count &gt;= 100 × 10^9/L

               -  Hemoglobin &gt;= 9 gram per deciliter (g/dL) (may have been transfused)

          -  Adequate hepatic function as defined below:

               -  A total bilirubin level &lt;= 1.5 × the upper limit of normal (ULN) range

               -  Aspartate aminotransferase (AST) levels &lt;= 2.5 × ULN

               -  Alanine aminotransferase (ALT) levels &lt;= 2.5 × ULN

               -  Subjects with documented Gilbert disease are allowed if total bilirubin &gt; 1.5
                  but less than 3 × ULN

          -  Adequate renal function as defined by an estimated creatinine clearance &gt;= 50
             milliliter per minute (mL/min) according to the Cockcroft-Gault formula

          -  Negative blood pregnancy test at Screening for women of childbearing potential. For
             the purposes of this trial, women of childbearing potential are defined as all female
             subjects after puberty unless they are postmenopausal for at least 1 year, are
             surgically sterile or are sexually inactive.

          -  Highly effective contraception (ie, methods with a failure rate of less than 1% per
             year) must be used before the start of treatment, for the duration of the trial
             treatment, and for at least 60 days after stopping trial participation for both men
             and women if the risk of conception exists. The effects of avelumab and NHS-IL12 on
             the developing human fetus are unknown; thus, women of childbearing potential and men
             must agree to use effective contraception.

        Exclusion Criteria:

          -  Concurrent treatment with a non-permitted drug/intervention (listed below)

               -  Anticancer treatment (eg, cytoreductive therapy, radiotherapy, immune therapy,
                  cytokine therapy, monoclonal antibody, targeted small molecule therapy) or any
                  investigational drug within 2 weeks prior to start of trial treatment, or not
                  recovered from adverse event (AE) related to such therapies, with the following
                  exceptions: Palliative bone-directed radiotherapy is permitted; Erythropoietin
                  and darbepoetin-α are permitted; Hormonal therapies acting on the
                  hypothalamic-pituitary-gonadal axis are permitted (i.e. luteinizing
                  hormone-releasing hormone agonist/antagonists). No other hormonal anticancer
                  therapy is permitted.

               -  Major surgery (as deemed by Investigator) for any reason, except diagnostic
                  biopsy, within 4 weeks prior to start of trial treatment, or not fully recovered
                  from surgery within 4 weeks prior to start of trial treatment

               -  Subjects receiving immunosuppressive agents (such as steroids) for any reason
                  should be tapered off these drugs before start of trial treatment, with the
                  following exceptions: Subjects with adrenal insufficiency, may continue
                  corticosteroids at physiologic replacement dose, equivalent to less than (&lt;) 10
                  mg prednisone daily; Administration of steroids through a route known to result
                  in a minimal systemic exposure (topical, intranasal, intro-ocular, or
                  inhalation) is permitted; Previous or ongoing administration of systemic
                  steroids for the management of an acute allergic phenomenon is acceptable as
                  long as it is anticipated that the administration of steroids will be completed
                  in 14 days, or that the dose after 14 days will be equivalent to &lt;= 10 mg
                  prednisone daily.

          -  Any prior treatment with any form of interlukin-12 (IL-12)

          -  Intolerance to checkpoint inhibitor therapy, as defined by the occurrence of an AE
             requiring drug discontinuation.

          -  Active or history of primary or metastatic central nervous system tumors

          -  Prior organ transplantation, including allogeneic stem-cell transplantation

          -  Previous malignant disease (other than the indication for this trial) within the last
             5 years (except adequately treated non-melanoma skin cancers, carcinoma in situ of
             skin, bladder, cervix, colon/rectum, breast, or prostate) unless a complete remission
             without further recurrence was achieved at least 2 years prior to trial entry and the
             subject was deemed to have been cured with no additional therapy required or
             anticipated to be required.

          -  Significant acute or chronic infections requiring systemic therapy including, among
             others:

               -  History of testing positive test for human immunodeficiency virus (HIV) or known
                  acquired immunodeficiency syndrome

               -  Hepatitis B or C infection (HBV surface antigen positive and HBV core antibody
                  positive with reflex to positive HBV deoxy ribonucleic acid (DNA) or HBV core
                  antibody positive alone with reflex to positive HBV DNA or positive hepatitis C
                  virus [HCV] antibody with reflex to positive HCV ribonucleic acid [RNA]).
                  Subjects with history of infection must have polymerase chain reaction
                  documentation that infection is cleared.

               -  Active tuberculosis (history of exposure or history of positive TB
                  (tuberculosis) test with presence of clinical symptoms, physical, or
                  radiographic finding

          -  Active or history of autoimmune disease that might deteriorate when receiving an
             immuno-stimulatory agent. Subjects with diabetes type I, vitiligo, psoriasis, hypo-
             or hyperthyroid disease not requiring immunosuppressive treatment are eligible.

          -  Known severe hypersensitivity reactions to monoclonal antibodies (Grade&gt;= 3 National
             Cancer Institute-Common Terminology Criteria for Adverse Event (NCI-CTCAE) v4.03, or
             uncontrolled asthma (ie, 3 or more features of partially controlled asthma)

          -  History of allergic reaction to methotrexate (trace methotrexate may be present in
             NHS-IL12 as a part of the manufacturing process)

          -  Persisting toxicity related to prior therapy of Grade &gt; 1 NCI-CTCAE v4.03 with the
             following exceptions:

               -  Neuropathy Grade &lt;= 2 is acceptable.

               -  All grades of alopecia are acceptable.

               -  Endocrine dysfunction on replacement therapy is acceptable.

          -  Pregnancy or lactation

          -  Known alcohol or drug abuse as deemed by the Investigator

          -  Uncontrolled intercurrent illness including, but not limited to:

               -  Hypertension uncontrolled by standard therapies (not stabilized to 150/90
                  millimeter of mercury (mm Hg) or lower)

               -  Uncontrolled active infection

               -  Uncontrolled diabetes (eg, glycosylated hemoglobin [HgbA1c] &gt;= 8%)

          -  Clinically significant (or active) cardiovascular disease: cerebral vascular
             accident/stroke (&lt; 6 months prior to enrollment), myocardial infarction (&lt; 6 months
             prior to enrollment), unstable angina, congestive heart failure (New York Heart
             Association Classification Class &gt;= II), or serious cardiac arrhythmia requiring
             medication

          -  All other significant diseases (eg, inflammatory bowel disease, current severe acute
             or chronic colitis) or chronic medical conditions (including laboratory
             abnormalities) that in the opinion of the Investigator might impair the subject's
             tolerance of trial treatment or interpretation of trial results.

          -  Any psychiatric condition that would prohibit the understanding or rendering of
             informed consent or that would limit compliance with trial requirements

          -  Legal incapacity or limited legal capacity

          -  Administration of a live vaccine within 30 days prior to trial entry

          -  Any subject with possible area of ongoing necrosis (non-disease related), such as
             active ulcer, non-healing wound, or intercurrent bone fracture that may be at risk of
             delayed healing due to protocol therapy

          -  Oxygen saturation &lt; 90% at rest, known pulmonary fibrosis, or active interstitial
             lung disease

          -  History of congenital or active immunodeficiency, with the exception of acquired
             treatment-related hypogammaglobulinemia requiring periodic IV immunoglobulin
             infusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James L. Gulley</last_name>
      <phone>301-480-8870</phone>
    </contact>
    <investigator>
      <last_name>James L. Gulley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>For Recruiting Locations in United States, please Contact U.S. Medical Information</name>
      <address>
        <city>Rockland</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 18, 2017</lastchanged_date>
  <firstreceived_date>December 14, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Avelumab</keyword>
  <keyword>M9241</keyword>
  <keyword>NHS-IL12</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interleukin-12</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
